Physician profile
Rene A Leon
NPI 1639255896
$47,609.35
in general payments reported to CMS, 2019-2025
51 companies · $3,311 in 2025
The $3,311 reported for 2025 was more than what 81% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $8,935 · 2021: $6,911 · 2022: $6,055 · 2023: $3,186 · 2024: $2,822 · 2025: $3,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,047 · Consulting Fee: $940 · Education: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,047.15 |
| Consulting Fee | $939.68 |
| Education | $332.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14,231.46 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $11,350.23 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $4,560.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,265.03 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Pfizer INC. | $2,092.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,511.19 | 2020-2025 | Takhzyro, Hyqvia, Eohilia |
| Csl Behring | $910.71 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Abbvie INC. | $895.43 | 2021-2025 | |
| Pharming Healthcare, INC. | $785.34 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $627.21 | 2019-2025 | Xolair |
| Amgen INC. | $598.12 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $559.39 | 2019-2025 | |
| Covis Pharma Gmbh | $510.26 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $483.62 | 2019-2022 | |
| Blueprint Medicines Corporation | $468.08 | 2023-2025 | Ayvakit |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $451.10 | 2022-2025 | Adbry |
| Mylan Specialty L.P. | $417.86 | 2019-2024 | Yupelri |
| Insmed, INC. | $324.38 | 2024-2025 | Brinsupri, Arikayce |
| Optinose US, INC. | $323.90 | 2019-2025 | |
| Grifols USA, LLC | $316.07 | 2019-2025 | Xembify |
| Biocryst US Sales Co., LLC | $310.90 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $254.31 | 2020-2024 | Auvi-Q |
| Octapharma USA, INC. | $252.17 | 2019-2024 | Panzyga |
| Sanofi-Aventis U.S. LLC | $245.15 | 2020-2025 | |
| Shire North American Group INC | $216.90 | 2019 | |
| Ionis Pharmaceuticals, INC. | $190.85 | 2025 | Dawnzera, Donidalorsen |
| Alk-Abello, INC | $187.03 | 2019-2022 | |
| Lilly USA, LLC | $147.24 | 2024 | Ebglyss, Taltz |
| Organon LLC | $144.77 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $122.84 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.70 | 2019-2022 | |
| Incyte Corporation | $97.98 | 2021-2024 | Opzelura |
| Viatris Specialty LLC | $78.50 | 2025 | Yupelri |
| Galderma Laboratories, L.P. | $65.90 | 2024-2025 | Nemluvio |
| Verona Pharma, INC. | $47.06 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $46.12 | 2019-2023 | |
| Philips North America LLC | $43.49 | 2020-2023 | |
| Genentech, INC. | $39.95 | 2019 | |
| Adma Biomanufacturing LLC | $37.18 | 2023 | |
| Mylan Pharmaceuticals INC. | $32.74 | 2019 | |
| Biocryst Pharmaceuticals, INC. | $32.68 | 2020 | |
| Tersera Therapeutics LLC | $32.54 | 2025 | Quzyttir |
| Azurity Pharmaceuticals, INC. | $32.28 | 2025 | Alvesco |
| Aytu Biopharma, INC. | $25.30 | 2020 | |
| Phadia US INC. | $25.20 | 2025 | Immunocap |
| Eyevance Pharmaceuticals LLC | $24.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.60 | 2021 | |
| Baxter Healthcare | $18.18 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Dermavant Sciences, INC. | $17.84 | 2023 | Vtama |
| Karl Storz Endoscopy-America | $13.50 | 2023 | Hopkins |
| Monaghan Medical Corporation | $6.84 | 2024 | Aerochamber |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.